Compare AERT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | IMMP |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | Singapore | Australia |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 42.4M |
| IPO Year | 2021 | 2012 |
| Metric | AERT | IMMP |
|---|---|---|
| Price | $7.10 | $0.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 14.7K | ★ 324.8K |
| Earning Date | 02-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.87 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $70,014,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.26 |
| 52 Week High | $7.65 | $3.53 |
| Indicator | AERT | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 29.26 |
| Support Level | $6.11 | N/A |
| Resistance Level | $7.30 | $0.40 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 64.19 | 7.86 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.